A Dark Vector Cognition product

Item 6. EXHIBITS

2K characters. Original on sec.gov ·

Item 6. EXHIBITS

(a) List of Exhibits:

22—List of Subsidiary Guarantors and Pledged Securities.
31.1—Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2—Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32—Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101—The following financial information from our quarterly report on Form 10-Q for the quarter ended September 30, 2023 filed with the SEC on October 26, 2023, formatted in Inline Extensible Business Reporting Language: (i) the condensed consolidated balance sheets at September 30, 2023 and December 31, 2022, (ii) the condensed consolidated income statements for the quarters and nine months ended September 30, 2023 and 2022, (iii) the condensed consolidated comprehensive income statements for the quarters and nine months ended September 30, 2023 and 2022, (iv) the condensed consolidated statements of stockholders’ equity (deficit) for the quarters and nine months ended September 30, 2023 and 2022, (v) the condensed consolidated statements of cash flows for the nine months ended September 30, 2023 and 2022 and (vi) the notes to condensed consolidated financial statements. The instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.
104—The cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, formatted in Inline XBRL (included in Exhibit 101).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HCA Healthcare, Inc.
By:/S/ WILLIAM B. RUTHERFORD
William B. Rutherford
Executive Vice President and Chief Financial Officer

Date: October 26, 2023

Previous: Item 5. OTHER INFORMATION